Stewart Sherri L, Harewood Rhea, Matz Melissa, Rim Sun Hee, Sabatino Susan A, Ward Kevin C, Weir Hannah K
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):5138-5159. doi: 10.1002/cncr.31027.
Ovarian cancer is the fifth leading cause of cancer death among women in the United States. This study reports ovarian cancer survival by state, race, and stage at diagnosis using data from the CONCORD-2 study, the largest and most geographically comprehensive, population-based survival study to date.
Data from women diagnosed with ovarian cancer between 2001 and 2009 from 37 states, covering 80% of the US population, were used in all analyses. Survival was estimated up to 5 years and was age standardized and adjusted for background mortality (net survival) using state-specific and race-specific life tables.
Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than one-half were diagnosed at distant stage. Five-year net survival was 39.6% between 2001 and 2003 and 41% between 2004 and 2009. Black women had consistently worse survival compared with white women (29.6% from 2001-2003 and 31.1% from 2004-2009), despite similar stage distributions. Stage-specific survival for all races combined between 2004 and 2009 was 86.4% for localized stage, 60.9% for regional stage, and 27.4% for distant stage.
The current data demonstrate a large and persistent disparity in ovarian cancer survival among black women compared with white women in most states. Clinical and public health efforts that ensure all women who are diagnosed with ovarian cancer receive appropriate, guidelines-based treatment may help to decrease these disparities. Future research that focuses on the development of new methods or modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve overall US ovarian cancer survival. Cancer 2017;123:5138-59. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
卵巢癌是美国女性癌症死亡的第五大主要原因。本研究使用CONCORD - 2研究的数据报告了按州、种族和诊断时的分期划分的卵巢癌生存率,CONCORD - 2研究是迄今为止规模最大、地域覆盖最全面的基于人群的生存研究。
所有分析均使用了2001年至2009年间来自37个州、覆盖美国80%人口的被诊断为卵巢癌的女性的数据。生存情况估计长达5年,并使用特定州和特定种族的生命表进行年龄标准化和背景死亡率调整(净生存)。
在2001年至2009年间诊断出的172,849例卵巢癌中,超过一半在远处分期时被诊断出来。2001年至2003年期间的5年净生存率为39.6%,2004年至2009年期间为41%。尽管分期分布相似,但黑人女性的生存率始终低于白人女性(2001 - 2003年为29.6%,2004 - 2009年为31.1%)。2004年至2009年期间,所有种族综合的各分期生存率为:局限期86.4%,区域期60.9%,远处期27.4%。
当前数据表明,在大多数州,黑人女性与白人女性在卵巢癌生存率方面存在巨大且持续的差异。确保所有被诊断为卵巢癌的女性接受适当的、基于指南的治疗的临床和公共卫生努力可能有助于减少这些差异。未来专注于开发新方法或模式以在生存率相对较高的早期阶段检测卵巢癌的研究,可能会提高美国卵巢癌的总体生存率。《癌症》2017年;123:5138 - 59。2017年发表。本文为美国政府作品,在美国属于公共领域。